INS and Insulin resistance: A prospective cohort study involving 48 postmenopausal osteoporotic nondiabetic women showed that 1-month denosumab therapy decreased fasting insulin by 10.5 pmol/L and homeostatic model assessment of insulin resistance (HOMA-IR) by 0.5 (Table 1) [38].